offer
all report title image
  • Published On : Aug 2022
  • Code : CMI4481
  • Industry : Pharmaceutical
  • Pages : 211
  • Formats :

Drug compounding is the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient. Compounding includes the combining of two or more drugs, and compounded drugs are not FDA approved.

A drug may be compounded for a patient who cannot be treated with an FDA approved medication, such as patients who has an allergy to a certain dye and needs a medication to be made without it, or an elderly patient or a child who cannot swallow a tablet or capsule and needs a medicine in a liquid dosage form. Practitioners in hospitals, clinics, and other health care facilities sometimes provide compounded drugs to patients when an FDA approved drug is not medically appropriate to treat them.

Compounding commonly occurs in pharmacies, it may also occur in other settings, federal law addresses compounding by a licensed pharmacist in a state licensed pharmacy, or federal, or by a physician, as well as compounding by or under the direct supervision of licensed pharmacist in an outsourcing facility.

The U.S 503B compounding pharmacies market is estimated to be valued at US$ 985.6 million in 2022 and is expected to exhibit a CAGR of 7.6 % over the forecast period (2022-2030)

Figure 1. U.S 503B Compounding Pharmacies Market Value (US$ Mn), By Packaging Type, 2022

U.S. 503B Compounding Pharmacies  | Coherent Market Insights

Increasing availability of compounded preparation is expected to drive the market growth over the forecast period

For instance, in May 2020, Central Admixture Pharmacy Services, Inc. launched three new compounded sterile preparations, which are in short supply for ICU patients, the products are two vasodilators: Norepinephrine 8 mg added to 250 ml normal saline (NS), Vasopressin 50 units added to 50 ml NS and sedative: Midazolam 125 mg added to NS (1mg/ml)

Moreover, in November 2019, West Pharmaceuticals Services, Inc., a 503B outsourcing facility launched Ready Pack containment system, consisting of sterile, ready-to-use (RU) NovaPure stoppers, Daikyo Crystal Zenith cyclic olefin polymer vials and Flip-Off (clean, certified, sterilized) CCS seals.

CMI table icon

U.S. 503B Compounding Pharmacies Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 985.6 Mn
Historical Data for: 2017 to 2021 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 7.6 % 2030 Value Projection: US$ 1,766 Mn
Geographies covered:
  • U.S.
Segments covered:
  • By Molecule: Acetaminophen, Phenylephrine, Midazolam, Esmolol, Vancomycin, Epinephrine, Adenocaine, Fentanyl/ Bupivacaine, Morphine, Amiodarone, Heparin, Ketamine, Dextrose, Hydromorphone, Bupivacaine, Lidocaine, BKK (Bupivacaine, ketorolac, Ketamine), RCK (Ropivacaine, Clonidine, Ketorolac), RKK (Ropivacaine, Ketorolac, Ketamine), Other Molecules
  • By Packaging: Vials, Prefilled Syringes, Ampoules, Syringes, Others
Companies covered:

Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma.

Growth Drivers:
  • Increasing drug shortage in the U.S
  • Increasing geriatric population and improved longevity due to customized medicines
Restraints & Challenges:
  • Increasing product recalls
  • Risk associated with 503B compounding drugs

Figure 2. U.S. 503B Compounding Pharmacies Market Share (%), By Molecule Type, 2022

U.S. 503B Compounding Pharmacies  | Coherent Market Insights

Increasing facility expansion by the market players is expected to drive the market growth over the forecast period.

For instance, in September 2019, Quva Pharma, a FDA registered manufacturer of compounded medicines announced that it completed the facility expansion of the cGMP compliant 503B, the U.S. FDA registered manufacturing facility at Bloomsbury, New Jersey, U.S, and this has increased the facility by 160,000 square feet.

Moreover, in August 2021, Empower pharmacy, a compounding pharmacy which based in Texas, U.S. announced the grand opening of its new facility in Houston, U.S. This facility will allow Empower pharmacy to prepare thousands of custom prescription each day for millions of patients across the country.

U.S 503B Compounding Pharmacies Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 546,357,444 cases of coronavirus disease (COVID-19) were reported till 2 July, 2022, across the globe.

In the times of covid-19 pandemic pharmacies are struggling to fulfil the demand of the medicine. Consequently, 503B outsourcing facilities are proving to be crucial partners to health systems and hospital pharmacies in helping to fulfil drug scarcity and the impact on patients during the covid-19 pandemic. The Drug Quality and Security Act, passed in 2013, allowed 503B outsourcing facilities to compound certain nonsterile and sterile drugs products in anticipation of need by providers and based on meeting certain standards required by the U.S. FDA, with massive demand surged for critical care medicines because of the pandemic, 503B facilities can supplement hospitals when commercial manufacturers cannot supply.

Market Restraint

Increasing product recalls is expected to hamper the growth of the U.S. 503B compounding pharmacies market. For instance, in August 2019, the U.S Food and Drug Administration request recall of sterile compounded drug products produced by Pacifico National Inc., an outsourcing facility doing business as AmEx pharmacy, in Melbourne, Florida. The drugs which included compounded ophthalmic products among other drug products cause unnecessary risks due to significant quality and sterility concerns.

Key Players

Major players operating in the U.S. 503B compounding pharmacies market include Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma.

These are specialized types of drug manufacturing organizations that serve a critical role in the patient care, as stated by the United States Pharmacopoeia (USP), compounding provides access to medication for patients who may not be able to use commercially available formulations due to dosing requirements, allergies, or rare diseases. The 503B compounding pharmacies are required to be registered with the U.S. FDA and maintain full compliance with the current good manufacturing practices (cGMP).

The cGMP guidelines compounding pharmacies needs to follow are 503B compounding pharmacies are must validate every process according to CGMP.

503B facilities must produce multiple batches and submit them for testing and stability before a new product can be brought to market.

503B products and testing methods must be validated according to US pharmacopeia (USP). Similarly, all suppliers and vendors providing raw materials must be evaluated. Moreover, onsite inspection must be performed by quality personnel.

Market Dynamics

The increasing launches of 503B compounding pharmacies in the U.S and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the U.S. 503B compounding pharmacies market over the forecast period.

For instance, in January 2022, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announced the launch of Hikma 503B, a new outsourced sterile compounding business focused on providing high quality, ready to administer injectable medications that are customized to the specific need of patients in the U.S.

Key features of the study:

  • This report provides an in-depth analysis of the U.S. 503B compounding pharmacies market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. 503B compounding pharmacies market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S 503B Compounding pharmacies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. 503B compounding pharmacies market.

Detailed Segmentation:

  • U.S. 503B Compounding pharmacies Market, By Molecule:
    • Acetaminophen
    • Phenylephrine
    • Midazolam
    • Esmolol
    • Vancomycin
    • Epinephrine
    • Adenocaine
    • Fentanyl/ Bupivacaine
    • Morphine
    • Amiodarone
    • Heparin
    • Ketamine
    • Dextrose
    • Hydromorphone
    • Bupivacaine
    • Lidocaine
    • BKK (Bupivacaine, ketorolac, Ketamine)
    • RCK (Ropivacaine, Clonidine, Ketorolac)
    • RKK (Ropivacaine, Ketorolac, Ketamine)
    • Other Molecules
  • U.S 503B Compounding Pharmacies Market, By Packaging:
    • Vials
    • Prefilled Syringes
    • Ampoules
    • Syringes
    • Others
  • Company Profiles
    • Central Admixture Pharmacy Services, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Nephron Pharmaceuticals Corporation
    • QuVa Pharma
    • Olympia Pharmacy
    • ASP Cares
    • Fagron Compounding Pharmacies
    • Athenex, Inc.
    • Avella Specialty Pharmacy
    • Atlas Pharmaceuticals
    • Empower Pharmacy
    • Carie Boyd’S Prescription Shop
    • Edge Pharma, Imprimis NJOF
    • IntegraDose Compounding services
    • Wells Pharma of Houston, LLC
    • US Compounding Inc.
    • SCA Pharma

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The U.S. 503B compounding pharmacies market size is estimated to be valued at US$ 885.6 million in 2022 and is expected to exhibit a CAGR of 7.6 % between 2022 and 2030.
Increasing drug shortages is expected to drive growth of the market over the forecast period.
Prefilled syringes is the leading packaging type segment in the market.
Increasing product recalls is hampering the growth of the market.
Major players operating in the market include Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo